Literature DB >> 11920197

A comparison in normal individuals and sickle cell patients of reduced glutathione precursors and their transport between plasma and red cells.

K Kiessling1, N Roberts, J S Gibson, J C Ellory.   

Abstract

INTRODUCTION: Reduced glutathione is an important antioxidant in red cells whose depletion may contribute to the pathophysiology of sickle cell disease. The current study was designed to examine the availability of reduced glutathione precursors (glutamate, cysteine, glycine and possibly glutamine) together with the activity of the main transport pathways for their uptake (system ASC for cysteine and glycine; system gly for glycine).
MATERIALS AND METHODS: Blood samples were obtained from normal (HbAA, HbA cells) and sickle cell disease patients (HbSS, HbS cells); amino acids were measured by HPLC; and transporter activity was measured by radioactive tracer fluxes (using serine and glycine for activity of system ASC; and glycine for that of system gly).
RESULTS: Plasma concentrations of cysteine and glycine were increased and concentrations of all amino acids were elevated in HbS cells. The activity of system ASC was increased in HbS cells (both transport capacity and affinity were elevated for serine transport; transport capacity only for glycine). Activity of system gly was also increased (twofold increase in V(max) for glycine flux), though not significantly. Oxygenation also increased the activity of both transporters in normal and HbS cells. CO prevented deoxy-inhibition of glycine transport. Staurosporine (5 microM) inhibited O(2)-stimulated glycine transport through system ASC. It also inhibited the absolute magnitude of transport through system gly, but the O(2)-dependent flux was unaffected.
CONCLUSION: Low reduced glutathione levels in HbS cells were not due to decreased substrate availability and O(2) stimulated transport of reduced glutathione precursors in both normal and HbS cells, through a mechanism that is likely to involve Hb and possibly protein phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11920197     DOI: 10.1038/sj.thj.6200033

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  9 in total

1.  Metabolomics of ADSOL (AS-1) red blood cell storage.

Authors:  John D Roback; Cassandra D Josephson; Edmund K Waller; James L Newman; Sulaiman Karatela; Karan Uppal; Dean P Jones; James C Zimring; Larry J Dumont
Journal:  Transfus Med Rev       Date:  2014-02-05

Review 2.  L-glutamine for sickle cell disease: Knight or pawn?

Authors:  Alina Sadaf; Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-27

3.  Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.

Authors:  Jon A Detterich; Honglei Liu; Silvie Suriany; Roberta M Kato; Patjanaporn Chalacheva; Bruke Tedla; Payal M Shah; Michael C Khoo; John C Wood; Thomas D Coates; Ginger L Milne; Joo-Yeun Oh; Rakesh P Patel; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2019-07-03       Impact factor: 7.376

4.  Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data.

Authors:  Julia E Raftos; Stephney Whillier; Philip W Kuchel
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

5.  Cysteine-iron promotes arginase activity by driving the Fenton reaction.

Authors:  Efemwonkiekie W Iyamu; Harrison Perdew; Gerald M Woods
Journal:  Biochem Biophys Res Commun       Date:  2008-08-30       Impact factor: 3.575

6.  Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

Authors:  Claudia R Morris; Jung H Suh; Ward Hagar; Sandra Larkin; D Anton Bland; Martin H Steinberg; Elliott P Vichinsky; Mark Shigenaga; Bruce Ames; Frans A Kuypers; Elizabeth S Klings
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

Review 7.  Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Authors:  Olujide O Olubiyi; Maryam O Olagunju; Birgit Strodel
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

8.  A Proposed Concept for Defective Mitophagy Leading to Late Stage Ineffective Erythropoiesis in Pyruvate Kinase Deficiency.

Authors:  Annelies Johanna van Vuren; Eduard Johannes van Beers; Richard van Wijk
Journal:  Front Physiol       Date:  2021-01-20       Impact factor: 4.566

9.  The influence of hydroxyurea on oxidative stress in sickle cell anemia.

Authors:  Lidiane de Souza Torres; Danilo Grünig Humberto da Silva; Edis Belini Junior; Eduardo Alves de Almeida; Clarisse Lopes de Castro Lobo; Rodolfo Delfini Cançado; Milton Artur Ruiz; Claudia Regina Bonini-Domingos
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.